Lowes: Four years on, Keydata's structured products still deliver



Advisers should not mistake Keydata the company and Keydata structured investments, writes Ian Lowes, founder of StructuredProductReview.com and managing director of Lowes Financial Management.

At the end of a recent conference on structured products a financial adviser stood up at the back of the audience and chastised the presenters because: “No-one has mentioned structured products were the reason Keydata went into administration”. To hear this raised again coming up to four years on from the event itself illustrates just how negative impressions can be perpetuated. The inference here is it was structured products that caused the failure of Keydata, which, of course, is simply not true. The failure of Keydata is once more in the spotlight with the Financial Services Comp...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read